

Circulating Tumor DNA Analyses as Markers of Recurrence Therapy for Stage III Colon Cancer

JAMA Oncology

5, 1710

DOI: [10.1001/jamaoncol.2019.3616](https://doi.org/10.1001/jamaoncol.2019.3616)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Is the Patient Cured?. JAMA Oncology, 2019, 5, 1695.	3.4	0
3	Postoperative CEA and Other Non-traditional Risk Factors for Colon Cancer Recurrence: Findings from Swedish Population-Based Data. Annals of Surgical Oncology, 2020, 27, 971-972.	0.7	3
4	Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Letters, 2020, 472, 108-118.	3.2	8
5	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Targeted Oncology, 2020, 15, 11-24.	1.7	65
6	The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review. Cancers, 2020, 12, 2808.	1.7	33
7	Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing. , 2020, , .		0
8	Machine learning identifies two autophagy-related genes as markers of recurrence in colorectal cancer. Journal of International Medical Research, 2020, 48, 030006052095880.	0.4	3
9	Implementation of the plasma MYCN / NAGK ratio to detect MYCN amplification in patients with neuroblastoma. Molecular Oncology, 2020, 14, 2884-2893.	2.1	6
10	Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extracellular matrix fibronectin. Theranostics, 2020, 10, 11127-11143.	4.6	14
11	Adjuvant chemotherapy in colon cancer: state of the art and future perspectives. Current Opinion in Oncology, 2020, 32, 370-376.	1.1	9
13	Circulating tumour DNA-guided adjuvant chemotherapy in colorectal carcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 334-336.	0.3	1
14	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. ESMO Open, 2020, 5, e001001.	2.0	11
15	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 581130.	1.3	7
16	Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut, 2020, 69, 2025-2034.	6.1	77
17	Adjuvant Chemotherapy for Stage III Colon Cancer. Cancers, 2020, 12, 2679.	1.7	44
18	Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Cancers, 2020, 12, 2277.	1.7	83
19	Circulating Tumor DNA in Cancer Management: A Value Proposition. journal of applied laboratory medicine, The, 2020, 5, 1017-1026.	0.6	0
20	Pathology of HPV-Associated Head and Neck Carcinomas: Recent Data and Perspectives for the Development of Specific Tumor Markers. Frontiers in Oncology, 2020, 10, 528957.	1.3	11

#	ARTICLE	IF	CITATIONS
21	Precision medicine for adjuvant chemotherapy of resected colorectal cancer. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 635-645.	1.2	5
22	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2441-2453.	1.1	5
23	Bioinformatic Identification of Hub Genes and Analysis of Prognostic Values in Colorectal Cancer. <i>Nutrition and Cancer</i> , 2021, 73, 2568-2578.	0.9	7
24	Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. <i>Visceral Medicine</i> , 2020, 36, 388-396.	0.5	4
25	Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?. <i>Human Genomics</i> , 2020, 14, 15.	1.4	29
26	The value of circulation tumor DNA in predicting postoperative recurrence of colorectal cancer: a meta-analysis. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1463-1475.	1.0	11
27	Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. <i>Current Opinion in Oncology</i> , 2020, 32, 364-369.	1.1	7
28	ctDNA monitoring using patient-specific sequencing and integration of variant reads. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	116
29	Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100024.	0.6	11
30	State of the Science and Future Directions for Liquid Biopsies in Drug Development. <i>Oncologist</i> , 2020, 25, 730-732.	1.9	9
31	<p>Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1621-1630.	0.9	20
32	Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches. <i>Cancers</i> , 2020, 12, 592.	1.7	3
33	Perspectives of the Application of Liquid Biopsy in Colorectal Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	40
34	Redefining Colorectal Cancer by Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 147-159.	1.8	9
35	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal"Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
37	Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms. <i>Laboratory Investigation</i> , 2020, 100, 1475-1484.	1.7	15
38	Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better. <i>Current Opinion in Oncology</i> , 2020, 32, 344-346.	1.1	0
39	Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN). <i>Cancer Treatment Reviews</i> , 2020, 85, 101992.	3.4	17

#	ARTICLE	IF	CITATIONS
40	Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer. <i>JAMA Oncology</i> , 2020, 6, 932.	3.4	2
41	Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 932.	3.4	1
42	Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection. <i>Endocrine</i> , 2020, 69, 430-440.	1.1	7
43	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , 2020, 86, 102023.	3.4	34
44	The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1845-1858.	0.7	5
45	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	2.3	77
46	Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. <i>Clinical Cancer Research</i> , 2021, 27, 141-149.	3.2	17
47	Liquid biopsy as a perioperative biomarker of digestive tract cancers: review of the literature. <i>Surgery Today</i> , 2021, 51, 849-861.	0.7	1
48	Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study. <i>Clinical Cancer Research</i> , 2021, 27, 301-310.	3.2	65
49	Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. <i>Gastroenterology</i> , 2021, 160, 690-709.	0.6	112
50	Dynamic analysis of circulating tumor <scp>DNA</scp> to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. <i>International Journal of Cancer</i> , 2021, 148, 921-931.	2.3	13
51	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 460-474.	2.6	67
52	Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 61-71.	1.2	4
53	In vitro anticancer activity of hydrogen sulfide and nitric oxide alongside nickel nanoparticle and novel mutations in their genes in CRC patients. <i>Scientific Reports</i> , 2021, 11, 2536.	1.6	13
54	Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 441.	1.6	13
55	ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis. <i>Future Oncology</i> , 2021, 17, 349-357.	1.1	3
56	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. <i>Advances in Cancer Research</i> , 2021, 151, 231-304.	1.9	8
57	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. <i>Diagnostics</i> , 2021, 11, 103.	1.3	33

#	ARTICLE	IF	CITATIONS
58	ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm. <i>Cancers</i> , 2021, 13, 346.	1.7	46
59	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 631-641.	0.8	63
60	Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection. <i>BMC Cancer</i> , 2021, 21, 179.	1.1	10
61	Dual inhibition of TGF β 2 and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , 2021, 38, 24.	1.2	7
62	Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 595650.	1.3	19
63	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. <i>Cancers</i> , 2021, 13, 659.	1.7	25
64	Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 144, 368-381.	1.3	34
65	Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling. <i>British Journal of Cancer</i> , 2021, 124, 1556-1565.	2.9	9
66	Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2890-2898.	3.2	44
67	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA. <i>Hepatology Communications</i> , 2021, 5, 1095-1105.	2.0	7
68	Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. <i>Cancers</i> , 2021, 13, 1612.	1.7	3
69	Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 650098.	1.3	41
70	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. <i>Oncologist</i> , 2021, 26, 651-659.	1.9	5
71	The robust performance of carcinoembryonic antigen levels after adjuvant chemotherapy for the recurrence risk stratification in patients with colorectal cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 97-105.	0.8	3
72	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	3.2	178
73	Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. <i>Annals of Oncology</i> , 2021, 32, 522-532.	0.6	53
74	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. <i>Seminars in Cancer Biology</i> , 2022, 84, 199-213.	4.3	35
75	How to use liquid biopsies to treat patients with cancer. <i>ESMO Open</i> , 2021, 6, 100060.	2.0	43

#	ARTICLE	IF	CITATIONS
76	Clinical relevance of circulating tumour DNA in colorectal cancer. ANZ Journal of Surgery, 2021, 91, 774-775.	0.3	1
77	Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy. Cancers, 2021, 13, 2231.	1.7	10
78	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Medicine, 2021, 18, e1003620.	3.9	88
79	Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology and Oncology, 2021, 14, 80.	6.9	90
80	The Emerging Role of Liquid Biopsy in Gastric Cancer. Journal of Clinical Medicine, 2021, 10, 2108.	1.0	20
81	Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Molecular Cancer, 2021, 20, 82.	7.9	58
82	Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer. Scientific Reports, 2021, 11, 13263.	1.6	1
83	Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. Pharmacoeconomics, 2021, 39, 953-964.	1.7	14
84	Elevated serum carcinoembryonic antigen level after curative surgery is a prognostic biomarker of stage II-III colorectal cancer. European Journal of Surgical Oncology, 2021, 47, 2880-2887.	0.5	10
85	Clinical implementation and current advancement of blood liquid biopsy in cancer. Journal of Human Genetics, 2021, 66, 909-926.	1.1	16
86	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial. Clinical Cancer Research, 2021, 27, 5638-5646.	3.2	42
87	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. Cancers, 2021, 13, 2762.	1.7	14
88	Perspectives for circulating tumor DNA in clinical management of colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 1420-1430.	1.0	3
89	ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC). Cancers, 2021, 13, 2869.	1.7	19
90	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 6343-6353.	3.2	8
91	Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies. Cancers, 2021, 13, 3522.	1.7	4
92	Mutational landscape of plasma cell-free DNA identifies molecular features associated with therapeutic response in patients with colon cancer. A pilot study. Mutagenesis, 2021, 36, 358-368.	1.0	5
93	Adjuvant Therapies in Colon Cancer. , 0, , .		0

#	ARTICLE	IF	CITATIONS
94	Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications. <i>Cancers</i> , 2021, 13, 3460.	1.7	15
95	The Provocative Roles of Platelets in Liver Disease and Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 643815.	1.3	10
96	Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA. <i>Npj Precision Oncology</i> , 2021, 5, 63.	2.3	23
97	Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection. <i>Gastroenterology</i> , 2021, 161, 1705-1708.e2.	0.6	8
98	Clinical Significance and Inflammatory Landscape of a Novel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 702594.	2.2	36
99	Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer. <i>Cancer Cell International</i> , 2021, 21, 359.	1.8	28
101	Postoperative Circulating Tumor DNA Can Predict High Risk Patients with Colorectal Cancer Based on Next-Generation Sequencing. <i>Cancers</i> , 2021, 13, 4190.	1.7	3
102	Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003741.	3.9	60
103	Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 37-45.	1.2	9
104	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. <i>Cancers</i> , 2021, 13, 4743.	1.7	8
105	Jagged-1 Expression Level Is Correlated With Recurrence of Stage III Colorectal Cancer in Patients Receiving Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2021, 41, 4645-4650.	0.5	1
106	Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4547.	1.7	12
107	Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2021, 20, 368-371.	1.0	1
109	Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. <i>Theranostics</i> , 2021, 11, 7018-7028.	4.6	37
110	Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. <i>Advances in Cancer Research</i> , 2021, 151, 425-468.	1.9	20
111	Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. <i>Annual Review of Medicine</i> , 2021, 72, 399-413.	5.0	12
112	Defining colon cancer biomarkers by using deep learning. <i>Lancet, The</i> , 2020, 395, 314-316.	6.3	8
113	Comment on "Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer". <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, e689-e690.	2.1	2

#	ARTICLE	IF	CITATIONS
115	Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World Journal of Gastrointestinal Oncology, 2020, 12, 808-832.	0.8	59
116	Liquid Biopsies for Molecular Biology-Based Radiotherapy. International Journal of Molecular Sciences, 2021, 22, 11267.	1.8	4
117	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Clinical Cancer Research, 2022, 28, 507-517.	3.2	104
118	A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers, 2021, 13, 5128.	1.7	6
119	Molecular testing for colorectal cancer: Clinical applications. World Journal of Gastrointestinal Oncology, 2021, 13, 1288-1301.	0.8	9
120	Circulating <scp>DNA</scp> changes are predictive of disease progression after transarterial chemoembolization. International Journal of Cancer, 2022, 150, 532-541.	2.3	5
121	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. Cancers, 2021, 13, 5299.	1.7	2
122	Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA nonâ€‘small cell lung cancer. Cancer, 2022, 128, 708-718.	2.0	39
123	Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact. Cancers, 2021, 13, 5364.	1.7	31
124	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). European Journal of Cancer, 2021, 159, 24-33.	1.3	24
126	The Revolution of Liquid Biopsy and Single-Cell Sequencing in the Management of Colorectal Cancer. , 2020, , 147-172.		1
128	Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?. Current Oncology Reports, 2021, 23, 140.	1.8	3
129	Circulating tumor DNA in colorectal cancer: opportunities and challenges. American Journal of Translational Research (discontinued), 2020, 12, 1044-1055.	0.0	14
130	polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer. American Journal of Cancer Research, 2021, 11, 1522-1539.	1.4	0
131	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Diseases of the Colon and Rectum, 2022, 65, 148-177.	0.7	118
132	Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer. JCO Precision Oncology, 2021, 5, 1788-1801.	1.5	4
133	A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer. Medical Science Monitor, 2022, 28, e934106.	0.5	3
134	Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. British Journal of Cancer, 2022, 126, 449-455.	2.9	15

#	ARTICLE	IF	CITATIONS
135	Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 763790.	1.3	60
136	Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. <i>Cancer Discovery</i> , 2021, 11, 2968-2986.	7.7	116
137	The impact of DNA testing on management of patients with colorectal cancer. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 17-28.	1.2	3
138	Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors. <i>Cancers</i> , 2021, 13, 5698.	1.7	31
139	Liquid biopsies for colorectal cancer: a narrative review of ongoing clinical trials and the current use of this technology at a comprehensive cancer center. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 438-449.	0.6	5
140	Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. <i>Annals of Surgical Oncology</i> , 2022, 29, 4583-4592.	0.7	4
141	Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent. <i>Journal of Clinical Oncology</i> , 2022, 40, 567-575.	0.8	83
142	Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. <i>Clinical Epigenetics</i> , 2022, 14, 3.	1.8	26
143	A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 427-438.	2.3	16
144	Ascites and Serial Plasma Circulating Tumor DNA for Predicting the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis. <i>Frontiers in Oncology</i> , 2022, 12, 791418.	1.3	1
145	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 811291.	1.1	2
146	Circulating tumor cell-free DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases. <i>International Journal of Cancer</i> , 2022, 150, 1537-1548.	2.3	22
147	Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies. <i>JCO Precision Oncology</i> , 2022, 6, e2100298.	1.5	6
148	A comprehensive framework for early-onset colorectal cancer research. <i>Lancet Oncology</i> , The, 2022, 23, e116-e128.	5.1	49
150	Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection. <i>Cancers</i> , 2022, 14, 642.	1.7	3
151	Utility of Cell-Free DNA Detection in Transplant Oncology. <i>Cancers</i> , 2022, 14, 743.	1.7	10
152	5mC-Related lncRNAs as Potential Prognostic Biomarkers in Colon Adenocarcinoma. <i>Biology</i> , 2022, 11, 231.	1.3	2
153	Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. <i>European Journal of Cancer</i> , 2022, 163, 163-176.	1.3	33

#	ARTICLE	IF	CITATIONS
154	Inhibition of tumor recurrence and metastasis <i>via</i> a surgical tumor-derived personalized hydrogel vaccine. <i>Biomaterials Science</i> , 2022, 10, 1352-1363.	2.6	18
155	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 235-247.	1.9	3
156	Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives. <i>Acta Oncologica</i> , 2022, 61, 523-530.	0.8	5
157	Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) – a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2022, 126, 1186-1195.	2.9	32
158	Metagenomics from bench to bedside and from bedside to bench. , 2022, , 157-187.		0
159	Systemic treatment of localized colorectal cancer. , 2022, , 257-271.		0
160	Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 830816.	1.3	3
161	Molecular genetic testing in colon cancer: clinical aspects. <i>Almanah Kliničeskoj Mediciny</i> , 0, , .	0.2	0
162	A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1955-1963.	1.2	8
163	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	1.5	33
164	Tumor-associated macrophages and risk of recurrence in stage III colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 307-312.	1.3	5
165	Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. <i>British Journal of Cancer</i> , 2022, 127, 592-602.	2.9	36
166	Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. <i>Molecular Cancer</i> , 2022, 21, 86.	7.9	72
167	Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e221093.	2.8	21
168	Colorectal Cancer Surveillance With Circulating Tumor DNA Assay. <i>JAMA Network Open</i> , 2022, 5, e221100.	2.8	7
169	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1800-1808.	3.2	26
170	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. <i>British Journal of Cancer</i> , 2022, 127, 394-407.	2.9	41
171	Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma. <i>Cancer Science</i> , 2022, 113, 1830-1842.	1.7	11

#	ARTICLE	IF	CITATIONS
172	Liquid Profiling for Cancer Patient Stratification in Precision Medicine—Current Status and Challenges for Successful Implementation in Standard Care. <i>Diagnostics</i> , 2022, 12, 748.	1.3	9
173	The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, 89-95.	1.0	10
174	Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 100.	0.4	4
175	The impact of subdivisions of microscopically positive (<scp>R1</scp>) margins on patterns of relapse in stage <scp>III</scp> colorectal cancer — A retrospective cohort study. <i>Colorectal Disease</i> , 2022, 24, 828-837.	0.7	4
176	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103647.	2.0	10
177	Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA. <i>EBioMedicine</i> , 2022, 78, 103945.	2.7	26
178	Colorectal liver metastases: state-of-the-art management and surgical approaches. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1765-1778.	0.8	7
179	Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, e793.	1.7	6
180	Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence—a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2022, , 1.	1.0	2
181	Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1215-1226.	0.9	1
182	SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 223-231.	1.5	3
183	Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer. <i>Cancer Biomarkers</i> , 2022, 34, 201-210.	0.8	2
184	Liquid biopsies for residual disease and recurrence. <i>Med</i> , 2021, 2, 1292-1313.	2.2	15
185	Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. <i>Biomarker Research</i> , 2021, 9, 91.	2.8	9
186	Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care. <i>Molecular Oncology</i> , 2022, 16, 2042-2056.	2.1	8
187	Early Detection of Circulating Tumor DNA Postoperatively Enables Discovery of Resectable Metastatic Disease in a Patient with Colon Cancer. <i>Case Reports in Oncology</i> , 2022, 14, 1748-1753.	0.3	3
188	Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4441.	1.8	30
189	CSCO guidelines for colorectal cancer version 2022: Updates and discussions. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 67-70.	0.7	20

#	ARTICLE	IF	CITATIONS
190	The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal. <i>Cancers</i> , 2022, 14, 2252.	1.7	8
191	Molecular genetic testing in colon cancer: clinical aspects. <i>AlĀ1manah KliniĀeskoj Mediciny</i> , 2022, 50, 1-12.	0.2	1
192	Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 279-298.	1.8	11
193	Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review. <i>Cancers</i> , 2022, 14, 2218.	1.7	16
194	Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5343.	1.8	3
195	Liquid biopsies to occult brain metastasis. <i>Molecular Cancer</i> , 2022, 21, 113.	7.9	23
196	New Insights into Adjuvant Therapy for Localized Colon Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, , .	0.9	1
197	Evaluation of cfDNA as an early detection assay for dense tissue breast cancer. <i>Scientific Reports</i> , 2022, 12, 8458.	1.6	3
198	Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study. <i>European Journal of Cancer</i> , 2022, 169, 198-209.	1.3	9
199	Integration of microfluidics with biosensing technology for noncommunicable disease diagnosis. , 2022, , 179-207.		0
200	Prognostic significance of additional histologic features for subclassification of pathological T3 colon cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1428-1438.	1.0	1
201	The current state of molecular profiling in gastrointestinal malignancies. <i>Biology Direct</i> , 2022, 17, .	1.9	5
202	Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)â€”Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC). <i>Cancers</i> , 2022, 14, 3078.	1.7	10
203	Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 26.	0.1	0
204	The prognostic value of circulating in blood tumor DNA as a marker of minimal residual disease in stage Iâ€”III colorectal cancer. <i>Uspehi Molekularnoj Onkologii</i> , 2022, 9, 32-42.	0.1	1
205	Mind the target: circulating tumour DNA in gastrointestinal malignancies. <i>Current Opinion in Oncology</i> , 2022, 34, 395-402.	1.1	2
206	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	0.6	204
207	Liquid profiling for cancer patient stratification in precision medicineâ€” current status and challenges for successful implementation in standard care. <i>Laboratoriums Medizin</i> , 2022, 46, 225-236.	0.1	1

#	ARTICLE	IF	CITATIONS
208	Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2023, 277, 813-820.	2.1	15
209	Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. <i>Journal of Clinical Oncology</i> , 2022, 40, 2846-2857.	0.8	77
210	Detection of methylated <i>BCAT1</i> and <i>IKZF1</i> after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence. <i>Cancer Medicine</i> , 2023, 12, 1319-1329.	1.3	5
211	Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	8
212	Comparing single-target and multitarget approaches for postoperative circulating tumour DNA detection in stage II-III colorectal cancer patients. <i>Molecular Oncology</i> , 2022, 16, 3654-3665.	2.1	7
213	Circulation tumour DNA in predicting recurrence and prognosis in operable colorectal cancer patients: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	4
214	Circulating DNA in the neoadjuvant setting of early stage colon cancer. <i>Acta Oncologica</i> , 2022, 61, 1223-1229.	0.8	4
215	SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
216	Bintrafusp Alfa, an Anti-PD-L1:TGF β Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. <i>Cancer Research Communications</i> , 2022, 2, 979-986.	0.7	9
217	Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101367.	0.5	0
218	Circulating Tumor DNA is Unreliable to Detect Somatic Gene Alterations in Gastrointestinal Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2023, 30, 278-284.	0.7	13
219	Bioplatfoms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. <i>Biotechnology and Genetic Engineering Reviews</i> , 2022, 38, 339-383.	2.4	8
220	Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers. <i>Clinical Chemistry</i> , 2022, 68, 1381-1390.	1.5	17
221	Serial Circulating Tumor DNA in Monitoring the Effect of Neoadjuvant and Adjuvant Immunotherapy in Patients With Colon Cancer: Case Series and Review of the Literature. <i>Journal of Immunotherapy</i> , 2022, 45, 358-362.	1.2	5
222	ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 8666-8674.	0.7	7
223	The impact of COVID-19 pandemic in the diagnosis and management of colorectal cancer patients. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211176.	1.4	8
224	Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
225	Glycosyltransferase-related long non-coding RNA signature predicts the prognosis of colon adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
226	Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers â€“ current evidence and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
227	Identification and validation of a 17-gene signature to improve the survival prediction of gliomas. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
230	Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1668.	3.4	15
231	Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11732.	1.8	6
232	Utility of Circulating Free DNA Fragmentomics in the Prediction of Pathological Response after Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Clinical Chemistry</i> , 2023, 69, 88-99.	1.5	11
233	Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen: Comparison of Surveillance Strategies Among Patients Who Underwent Resection of Colorectal Cancerâ€”A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2023, 30, 259-274.	0.7	4
234	Exosomal proteins as a source of biomarkers in colon cancerâ€“derived peritoneal carcinomatosis â€“ A pilot study. <i>Proteomics - Clinical Applications</i> , 0, , 2100085.	0.8	1
236	Advances in Cell-Free DNA. <i>Advances in Molecular Pathology</i> , 2022, 5, 141-148.	0.2	1
237	Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review. <i>Translational Lung Cancer Research</i> , 2022, 11, 2588-2600.	1.3	7
238	Ready for ctDNA-guided treatment decisions in colorectal cancer?. <i>Journal of the National Cancer Center</i> , 2023, 3, 1-3.	3.0	1
239	A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice. <i>Journal of Molecular Diagnostics</i> , 2023, 25, 36-45.	1.2	7
240	Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases. <i>JCO Precision Oncology</i> , 2022, , .	1.5	9
241	The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2023, 128, 297-309.	2.9	16
242	Circulating Tumour DNA and Risk-Stratified Surveillance Strategies for Patients with Colorectal Liver Metastases. , 2022, , 557-562.		0
243	Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211439.	1.4	3
244	Adjuvant Systemic Chemotherapy. , 2022, , 301-308.		0
245	The Negative Prognostic Impact of Lymph Node Skip Metastasis in Stage III Colon Cancer With pN1 Disease: A Single-Center and Retrospective Cohort Study. <i>Diseases of the Colon and Rectum</i> , 2023, 66, e1032-e1042.	0.7	1
246	Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer. <i>Cells</i> , 2022, 11, 3744.	1.8	9

#	ARTICLE	IF	CITATIONS
247	Predictive biomarkers of colon cancer immunotherapy: Present and future. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	30
248	Consequences of aberrated DNA methylation in Colon Adenocarcinoma: a bioinformatic-based multi-approach. <i>BMC Genomic Data</i> , 2022, 23, .	0.7	0
249	Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells. <i>Clinical Cancer Research</i> , 2023, 29, 899-909.	3.2	14
250	Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan. <i>Clinical Colorectal Cancer</i> , 2023, 22, 53-58.	1.0	3
251	Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	0
252	Prognostic value of elastic lamina staining in patients with stage III colon cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
253	Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
254	Single-Cell Analysis of Circulating Tumor Cells from Patients with Colorectal Cancer Captured with a Dielectrophoresis-Based Micropore System. <i>Biomedicines</i> , 2023, 11, 203.	1.4	3
255	Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2023, 34, .	1.0	1
256	Circulating DNA fragmentomics and cancer screening. <i>Cell Genomics</i> , 2023, 3, 100242.	3.0	15
257	Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1738.	1.8	2
258	Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. <i>Nature Medicine</i> , 2023, 29, 127-134.	15.2	88
259	Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer. <i>Oncolmmunology</i> , 2023, 12, .	2.1	7
260	Circulating tumor DNA-guided minimal residual disease assessment in colorectal cancer. <i>Pharmacogenomics</i> , 2023, 24, 1-4.	0.6	0
261	Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA. <i>Journal of Pathology</i> , 0, , .	2.1	1
262	The T-CEA score: a useful prognostic indicator based on postoperative CEA and pathological T4 levels for patients with stage II-III colorectal cancer. <i>Surgery Today</i> , 0, , .	0.7	1
263	Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. <i>JAMA Oncology</i> , 2023, 9, 404.	3.4	8
264	Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11

#	ARTICLE	IF	CITATIONS
265	Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1283-1290.	0.5	2
266	Extracellular Vesiclesâ€™ Genetic Cargo as Noninvasive Biomarkers in Cancer: A Pilot Study Using ExoGAG Technology. <i>Biomedicines</i> , 2023, 11, 404.	1.4	0
267	Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	1
268	ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?. <i>Current Treatment Options in Oncology</i> , 2023, 24, 76-92.	1.3	4
269	Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review. <i>Cost Effectiveness and Resource Allocation</i> , 2023, 21, .	0.6	0
270	MiSelect R System: the validation of a new detection system of CTCs and their correlation with prognosis in non-metastatic CRC patients. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
271	Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack?. <i>Cells</i> , 2023, 12, 1068.	1.8	1
272	CtDNAâ€™s prognostic value in patients with early-stage colorectal cancer after surgery: A meta-analysis and systematic review. <i>Medicine (United States)</i> , 2023, 102, e32939.	0.4	2
273	Construction and Validation of a Novel Prognosis Model in Colon Cancer Based on Cuproptosis-Related Long Non-Coding RNAs. <i>Journal of Clinical Medicine</i> , 2023, 12, 1528.	1.0	1
274	Regulatory implications of ctDNA in immuno-oncology for solid tumors. , 2023, 11, e005344.		10
275	Simple Detection and Culture of Circulating Tumor Cells from Colorectal Cancer Patients Using Poly(2-Methoxyethyl Acrylate)-Coated Plates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3949.	1.8	2
276	The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer. <i>Cancers</i> , 2023, 15, 1284.	1.7	5
277	Longitudinal ctDNA profiling in precision oncology and immunî-oncology. <i>Drug Discovery Today</i> , 2023, 28, 103540.	3.2	3
278	Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. <i>Cancers</i> , 2023, 15, 1473.	1.7	1
279	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 102-138.	0.5	14
280	Liver transplantation in metastatic colorectal cancer: are we ready for it?. <i>British Journal of Cancer</i> , 2023, 128, 1797-1806.	2.9	5
281	GLUT-1 may predict metastases and death in patients with locally advanced rectal cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
282	Circulating tumour DNA in the evolving treatment landscape of locally advanced rectal cancer: where does it fit in?. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311601.	1.4	2

#	ARTICLE	IF	CITATIONS
283	Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 195-200.	0.4	1
284	Locally performed postoperative circulating tumour <scp>DNA</scp> testing performed during routine clinical care to predict recurrence of colorectal cancer. <i>ANZ Journal of Surgery</i> , 2023, 93, 2473-2480.	0.3	1
285	A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. <i>Nature Medicine</i> , 2023, 29, 859-868.	15.2	30
286	Time for a lead-time definition? Author response to "Why the length of recurrence free survival or "lead-times" can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis"™. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311563.	1.4	1
287	ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C). <i>BMC Cancer</i> , 2023, 23, .	1.1	5
289	Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. <i>Annals of Surgery</i> , 2023, 278, 925-931.	2.1	3
290	Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 277-289.	0.4	0
291	Epigenetic liquid biopsies for minimal residual disease, whatâ€™s around the corner?. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
292	High-Throughput Profiling of Serological Immunoglobulin G N-Glycome as a Noninvasive Biomarker of Gastrointestinal Cancers. <i>Engineering</i> , 2023, 26, 44-53.	3.2	3
293	Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review). <i>Oncology Reports</i> , 2023, 49, .	1.2	4
294	Peritoneal cell-free DNA as a sensitive biomarker for detection of peritoneal metastasis in colorectal cancer: a prospective diagnostic study: A prospective diagnostic study. <i>Clinical Epigenetics</i> , 2023, 15, .	1.8	2
295	Progress in companion diagnosis of colorectal cancer. , 2023, 2, 63-66.		0
322	Practical recommendations for using ctDNA in clinical decision making. <i>Nature</i> , 2023, 619, 259-268.	13.7	17
323	Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	1
324	Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2023, , 127-143.	0.4	0
325	Role of Circulating Tumor DNA in Colorectal Cancer. <i>Methods in Molecular Biology</i> , 2023, , 227-236.	0.4	0
329	Diagnostic testing. , 2023, , 67-75.		0
330	Diagnostic discovery. , 2023, , 59-65.		0

#	ARTICLE	IF	CITATIONS
344	Utility of Circulating Tumor DNA in Appendiceal Tumors. Journal of Gastrointestinal Surgery, 2023, 27, 3071-3073.	0.9	0
345	Minimal residual disease in solid tumors: an overview. Frontiers of Medicine, 2023, 17, 649-674.	1.5	0
352	Personalizing adjuvant therapy for patients with colorectal cancer. Nature Reviews Clinical Oncology, 2024, 21, 67-79.	12.5	1
363	Epigenetic Alterations in Colorectal Cancer. Epigenetics and Human Health, 2023, , 331-361.	0.2	0